Education
About Us
Working with TipRanks
Follow Us
GNI Group (DE:3G6)
:3G6
3G6 Stock Chart & Stats
Day’s Range― - ―
52-Week Range€8.80 - €24.40
Previous CloseN/A
Volume0.00
Average Volume (3M)2.00
Market Cap
€926.04M
Enterprise Value€115.64B
Total Cash (Recent Filing)€10.12B
Total Debt (Recent Filing)¥7.21B
Price to Earnings (P/E)104.7
Beta1.67
Next Earnings
Aug 18, 2025EPS Estimate
0.75Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-0.07
Shares Outstanding50,526,943
10 Day Avg. Volume8
30 Day Avg. Volume2
Financial Highlights & Ratios
PEG Ratio-1.39
Price to Book (P/B)3.25
Price to Sales (P/S)0.00
P/FCF Ratio-28.90
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price TargetN/A
Price Target UpsideN/A
Rating ConsensusN/A
Number of Analyst Covering0
GNI Group News
PremiumCompany Announcements
GNI Group’s Liver Fibrosis Drug Achieves Key Trial Success in China
PremiumCompany Announcements
Gyre Therapeutics Launches $20 Million Public Stock Offering
PremiumCompany Announcements
GNI Group Reports Decline in Q1 FY2025 Financial Results
PremiumCompany Announcements
GNI Group Confirms NDA Timeline for HydronidonePremiumCompany Announcements
GNI Group Issues Stock Options Tied to Drug Approval MilestonePremiumCompany Announcements
GNI Group Projects Record Sales and Profits Amid U.S.-China Tariff Concerns
PremiumCompany Announcements
GNI Group Amends FY2024 Financial Results Following Tax Review
PremiumCompany Announcements
GNI Group Reports FY2024 Financial Decline, Projects Growth in FY2025Options Prices
Currently, No data available
---
Ownership Overview
―
Insiders
0.45%
Mutual Funds
― Other Institutional Investors
97.15% Public Companies and
Individual Investors
3G6 FAQ
What was GNI Group ’s price range in the past 12 months?
GNI Group lowest stock price was €8.80 and its highest was €24.40 in the past 12 months.
What is GNI Group ’s market cap?
GNI Group ’s market cap is €926.04M.
When is GNI Group ’s upcoming earnings report date?
GNI Group ’s upcoming earnings report date is Aug 18, 2025 which is in 86 days.
How were GNI Group ’s earnings last quarter?
GNI Group released its earnings results on May 15, 2025. The company reported -€0.065 earnings per share for the quarter, missing the consensus estimate of €0.171 by -€0.236.
Is GNI Group overvalued?
According to Wall Street analysts GNI Group ’s price is currently Overvalued.
Does GNI Group pay dividends?
GNI Group does not currently pay dividends.
What is GNI Group ’s EPS estimate?
GNI Group ’s EPS estimate is 0.75.
How many shares outstanding does GNI Group have?
GNI Group has 50,526,943 shares outstanding.
What happened to GNI Group ’s price movement after its last earnings report?
GNI Group reported an EPS of -€0.065 in its last earnings report, missing expectations of €0.171. Following the earnings report the stock price went down -2.721%.
Which hedge fund is a major shareholder of GNI Group ?
Currently, no hedge funds are holding shares in DE:3G6
Company Description
GNI Group
GNI Group Ltd. engages in the research, development, manufacture, and sale of pharmaceutical drugs and traditional Chinese medicines in Japan and internationally. It provides Etuary for the treatment of idiopathic pulmonary fibrosis. The company is also developing Etuary, which is in Phase III clinical trial for the treatment of connective tissue associated interstitial lung disease; and in clinical trial phase II and pre-phase III clinical trial pilot study for the treatment of radiation pneumonitis, as well as for the treatment of diabetic nephropathy. In addition, it is involved in developing F351, which is in Phase II clinical trial for the treatment of liver fibrosis; and F573 that is in pre-clinical phase for the treatment of acute on chronic liver failure, as well as Tamibarotene for the treatment of acute promyelocytic leukemia. GNI Group Ltd. was incorporated in 2001 and is headquartered in Tokyo, Japan.